相关临床试验
238
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
Available
1
0.4%
已完成
53
22.3%
Enrolling By Invitation
2
0.8%
尚未招募
9
3.8%
招募中
16
6.7%
暂停
1
0.4%
终止
3
1.3%
Unknown
153
64.3%
暂无批准数据
- A 47-year-old woman with three concurrent autoimmune diseases achieved complete symptom resolution after receiving a single dose of CAR-T cell therapy at University Hospital Erlangen in Germany. - The patient had autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome, requiring daily blood transfusions and failing nine previous treatments. - Within seven days of CAR-T treatment, the bedridden patient was mobile, and after 11 months remains medication-free with normal blood parameters. - This represents the first successful treatment of three simultaneous autoimmune conditions with a single CAR-T therapy, demonstrating the potential for this approach across multiple autoimmune diseases.
- The phase 3 FZOCUS-1 trial demonstrated that fuzuloparib monotherapy significantly improved progression-free survival compared to placebo in patients with newly diagnosed advanced ovarian cancer. - Adding apatinib to fuzuloparib did not provide additional benefit over fuzuloparib alone, marking the first study to show that combining an antiangiogenic agent with a PARP inhibitor does not improve outcomes in BRCA-mutated or HRD-positive ovarian cancer. - Fuzuloparib monotherapy achieved a median PFS of 29.9 months versus 11.1 months with placebo, representing a 42% reduction in disease progression risk. - The safety profile was consistent with previous PARP inhibitor studies, with hematological toxicities being the most common grade 3 or higher adverse events.
- Researchers at the National Cancer Center of China demonstrated that circulating tumor DNA (ctDNA) monitoring can identify which limited-stage small cell lung cancer patients will benefit from consolidation immunotherapy. - The study of 177 patients showed consolidation immune checkpoint inhibitors improved overall survival with a 59% reduction in death risk compared to chemoradiotherapy alone. - Patients with detectable ctDNA after induction chemotherapy derived substantial survival benefits from immunotherapy, while ctDNA-negative patients showed no added benefit. - This precision medicine approach could spare patients from unnecessary toxic treatments while optimizing outcomes for those most likely to respond.
- Keymed Biosciences' CM336, a BCMA x CD3 bispecific antibody, achieved rapid partial remission in two patients with refractory autoimmune hemolytic anemia within 13-19 days of treatment. - Both patients maintained sustained remission for over six months without requiring immunosuppressive therapies or transfusions, marking the first global report of BCMA-targeted therapy for this indication. - The treatment demonstrated excellent safety with no cytokine release syndrome, neurotoxicity, or infections during the entire treatment and follow-up period. - CM336 represents a potential breakthrough for patients with relapsed/refractory AIHA who have exhausted multiple conventional therapies including CAR-T cell treatments.
- Phase 1/2 study data presented at the 2025 AACR Annual Meeting revealed promising efficacy of fruquintinib plus capecitabine as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer patients. - At a median follow-up of 5.7 months, the disease control rate reached 90.9% with median progression-free survival not yet reached, and two patients experienced disease control lasting more than 430 days. - The recommended phase 2 dose was established at 5 mg daily of fruquintinib on days 1-14 of each 3-week cycle, with a manageable safety profile showing 87.5% of patients experiencing treatment-related adverse effects, mostly mild to moderate.
- Toripalimab induction therapy plus chemotherapy significantly improved progression-free survival compared to chemotherapy alone in patients with bulky, unresectable stage III non-small cell lung cancer, with 1-year PFS rates of 85.6% versus 54.5%. - The treatment reduced the risk of disease progression or death by 74% (HR 0.26, P=0.012) and achieved a significantly higher objective response rate of 77.8% compared to 40.0% with chemotherapy alone. - The combination demonstrated manageable toxicity with no grade 4 or 5 pneumonitis events, while grade 1/2 pneumonitis occurred in 37% of toripalimab patients versus 48% in the chemotherapy-only group. - Results from the randomized phase 2 InTRist study support advancing to phase 3 trials for this promising treatment strategy in high-risk lung cancer patients.
- A phase II trial showed that chemoradiation followed by immunochemotherapy and surgery improved outcomes in patients with unresectable, locally advanced esophageal squamous cell carcinoma. - The combination therapy led to a high rate of tumor resectability (66.7%) and pathologic complete response (65.0%) in treated patients. - The 1-year progression-free survival rate was 79.4%, and the 1-year overall survival rate was 89.6% with the novel treatment approach. - R0 resection was associated with significantly longer progression-free and overall survival compared to patients who did not undergo surgery.
- A Phase II trial demonstrates the safety and efficacy of chemoradiotherapy followed by tislelizumab-based immunochemotherapy in patients with unresectable esophageal squamous cell carcinoma. - The study achieved a 66.7% resectability rate, with 95.2% of resected patients achieving R0 resection, indicating no residual tumor after surgery. - Patients who underwent surgery had significantly longer progression-free survival and overall survival compared to those who did not. - The combination therapy showed manageable safety profiles, with common adverse events including radiation esophagitis and pneumonitis.
